- Biography
- Locations
- Specialties & Details
- Clinical Trials
- Related Stories
Biography
Dr. Brian Weiss is the pediatric division chief of hematology/oncology/stem cell transplant at Riley Children's Health. He comes to Riley Children's after his tenure at Cincinnati Children's Hospital Medical Center, where he previously served as professor of clinical pediatrics in the division of oncology, medical director of solid tumors, associate inpatient director, associate director of safety and compliance of the cancer and blood diseases institute. Prior to his time there, he completed residency and a fellowship at the University of California at San Francisco.
With his clinical expertise, he has stewarded multiple national clinical trials, particularly focusing on novel therapies for neuroblastoma and Neurofibromatosis Type 1 associated plexiform neurofibromas.
Dr. Weiss is excited to lead the dynamic group at Riley Children's and spearhead novel therapies for children with cancer and blood diseases.
Locations
Specialties & Details
Specialties:
Pediatric Hematology - Oncology
Conditions & Treatments:
Novel Therapies For Neuroblastoma & Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
Education
School of Medicine:
Northwestern University Feinberg School of Medicine, Chicago, IL
Residency:
University of California School of Medicine, San Francisco, CA
Fellowship:
University of California School of Medicine, San Francisco, CA
Hospitals & Affiliations
Hospital Privileges:
IU Health North, IU Health Methodist/IU Health University
Physician Group:
IU Health Medical Group, Riley Physicians
Research
Clinical Trials
Explore the ongoing clinical trials this provider is involved in and learn about the eligibility requirements for each one. Search the clinical trial directory to find additional clinical trials.
A Phase 1/2 Trial of CBL0137 in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma
View DetailsTegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
View DetailsA Phase 1 study of GRN163L (Imetelstat, IND# 170891, NSC# 754228) in combination with fludarabine and cytarabine for patients with acute myeloid leukemia that is in second or greater relapse or that is refractory to relapse therapy; myelodysplastic syndrome or juvenile myelomonocytic leukemia in first or greater relapse or is refractory to relapse therapy
View DetailsRelated Stories
Philanthropy fuels Master Clinician impact
Assembling a significant cohort of top medical cli...